Cannabis Therapy Targets Low-Hanging Fruit with Experienced Team


Ryan Allway

June 10th, 2014

News, Top Story


[stockchart symbol=”CTCO”]

The U.S. cannabis industry grew 64% in 2013 and is expected to reach $2.34 billion by the end of 2014, according to ArcView Market Research. At the same time, the U.S. nutraceutical industry is projected to grow at a 5% CAGR to reach $75.9 billion by 2018, according to RNCOS. Cannabis Therapy [stockquote symbol=”CTCO”] is executing its product development strategy to benefit from both of these trends, bringing biomedical methods and processes, as well as a seasoned management team, to the cannabis space.

In an exclusive interview, the company’s President and CEO Soren Mogelsvang sat down with CannabisFN’s Mike Elliott to discuss the company’s distinctive business model and how it plans to capitalize on the rapidly growing industries.

Qualified to Lead

Cannabis Therapy’s skilled team consists of entrepreneurs and business veterans with experience across both the nutraceutical and biomedical industries. President and CEO Soren Mogelsvang is a biotech executive with over 15 years of experience in translational research, antibody development, and ISO compliant manufacturing with proven development and operational skills.

On the Board of Directors, Guy Yachin, Cohava Gelber, and Vered Caplan bring an accomplished track record from the biomedical industry. Mr. Yachin is a serial biotech entrepreneur with a highly successful track record; Dr. Gelber is a PhD with over 25 years of work in developing immune-based therapeutics and diagnostics targeting cancer. Ms. Caplan brings to the table a diverse background in the biotech industry, having worked at several companies over the course of her career.

The team’s extensive background within the biotechnology and pharmaceutical industries could prove invaluable in guiding the company through the challenging early-stage cannabis industry. While pursuing a strategy with minimal regulatory hurdles, the team’s experience should ensure that its products are supported by science as well as being safe and efficacious for consumers.

Innovative Strategy

Cannabis Therapy differs from many other publicly traded medical cannabis companies, such as GW Pharmaceuticals plc (NASDAQ: GWPH) or Cannabis Science Inc. (OTC: CBIS), in that it’s focus is to target the nutraceutical industry. By taking this approach, management aims to minimize many of the regulatory hurdles associated with pushing a pharmaceutical drug through the FDA approval process.

The company aims to identify existing hemp-based cannabis strains and develop new proprietary cultivars with elevated cannabinoid content and little or no THC. With an ISO-compliant cannabinoid extraction and characterization process, the firm will adhere to strict biotechnology and pharmaceutical standards in its development and manufacturing of new products for the nutraceutical market.

In addition to developing nutraceuticals, management indicated that it may also offer laboratory purification and testing services, along with third party product development, to a select group of industry partners in the future. The combination of developing proprietary products and potentially joint venturing to develop additional products could create a comprehensive portfolio with less risk.

Clinically Significant

The hemp plant contains over 450 different substances and is practically devoid of the psychoactive THC (which creates the “high” feeling associated with marijuana). Researchers have been drawn to the human cannabinoid receptors and their potential to modulate the immune system, and positively influence human health.

Cannabis Therapy plans to focus its initial efforts on developing products for inflammatory diseases, where hemp has already been shown to have medicinal potential. Future products could target indications such as nausea, loss of appetite, insulin resistance, sleep disorders, anxiety, and chronic pain, leveraging the vast medicinal potential of the cannabis plant.

Looking Ahead

Cannabis Therapy has assembled a talented team and formulated a unique strategy to capitalize on the growing cannabis and nutraceutical industries. Since hemp is widely available and legal to grow in many states (due to its low THC content) the company’s products will likely face little regulatory scrutiny, while scientific studies have suggested that its products could be highly efficacious.

Investors may want to take a closer look at the company as an alternative to companies like Vape Holdings Inc. (OTC: VAPE) or Hemp Inc. (OTC: HEMP).

To Sign Up For Future Email Updates:
http://www.tdmfinancial.com/emailassets/ctco/ctco_landing.php

For more information, see the following resources:

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.



Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading